Left Bundle Branch Area Pacing (LBBAP) PMCF Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAbbott Medical Devices

About this trial

The objective of this study is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients implanted with the Tendril STS 2088TC or UltiPace LPA1231 lead through 6 months post-implant.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Meets current clinical practice guidelines for implantation of Tendril STS 2088TC or UltiPace LPA1231 lead in the Left Bundle Branch Area

Are ≥ 18 years of age or age of legal consent, whichever age is greater.

Subject is willing to comply with clinical investigation procedures and agrees to return to clinic for all required follow-up visits, tests, and exams.

Subject has been informed of the nature of the clinical investigation, agrees to its provisions and has provided a signed written informed consent, approved by the IRB/EC.

Disqualifiers

the presence of tricuspid atresia

patients with mechanical tricuspid valves

patients who are expected to be hypersensitive to a single dose of one milligram of dexamethasone sodium phosphate

Patient is currently implanted with a pacemaker, ICD, or CRT-D/P device

Trial design

Design model

Single group

Treatments tested in this trial

  • LBBAP lead

    Device

    The lead is bipolar, steroid-eluting, active fixation, MR Conditional, implantable pacing leads that can be placed in the right atrium, right ventricle, or left bundle branch area for pacing and sensing.

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: Left Bundle Branch Area Pacing Lead ImplantExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Infection Rate

Rate of Infection

Time frame
0-6 months
2

Perforation Rate

Perforation includes cardiac perforation, septal perforation, coronary sinus dissection, pericardial effusion, and cardiac tamponade.

Time frame
0-6 months
3

Malfunction Rate

Malfunction includes 1) mechanical lead failure including lead insulation issues, lead fracture, and other lead damage, dysfunction, helix damage or fracture; malfunction or failure; and 2) electrical abnormalities of unknown cause including sensing issues, pacing issues, loss of capture, impedance abnormality, and noise; 3) excludes infection, perforation or dislodgement caused inappropriate therapy.

Time frame
0-6 months
4

Cardiovascular Injury Rate

Cardiovascular Injury is a safety measure specific to LBBAP leads and includes Acute coronary syndrome; Coronary artery fistula; Coronary vein fistula/injury and Septal hematoma. This parameter also includes the right bundle branch block and complete heart block (permanent).

Time frame
0-6 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.